UBS has lowered its price target for Teradyne shares from $485 to $430, while reiterating a Buy rating. This adjustment follows the company's recent Q3 2026 financial results and updated guidance, indicating a revised valuation perspective from the analyst.
UBS has adjusted its price target for Teradyne (TER) shares downwards from $485 to $430. This change, while still maintaining a 'Buy' rating, reflects a revised valuation based on the company's recently reported third-quarter 2026 financial results and updated guidance. For traders, this indicates that while the long-term outlook remains positive according to UBS, the near-term growth trajectory or valuation multiples may have been tempered. The short-term implication is potential downward pressure on the stock as investors react to the lower price target, despite the maintained 'Buy' rating. The long-term implication depends on whether the underlying business fundamentals justify the revised target and if the company can exceed future expectations.